OpenScience.ink

6 days ago • Journal of general internal medicine

Costs and Affordability of Diabetes Drugs Like GLP-1 Agonists in the US from 2013 to 2023Spending and Affordability of Glucagon-Like Peptide-1 Receptor Agonists and Other Incretin Mimetics in the United States, 2013-2023.

🥉 Top 5% JournalArticle

6 days ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

Incretin-Based Medications and Their Effects on Women's Reproductive Health: Review and Clinical GuidelinesIncretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice.

Article

6 days ago • Tobacco induced diseases

GLP-1 drugs for quitting smoking and managing weight after quitting: A review and combined analysis of clinical trialsGLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.

📖 Top 30% JournalArticle

6 days ago • Regulatory toxicology and pharmacology : RTP

40-week safety, body processing, and immune response to repeated doses of efsubaglutide alfa under the skin in monkeys40-week repeat-dose toxicity, toxicokinetics, and immunogenicity of efsubaglutide alfa following subcutaneous administration in cynomolgus monkeys.

📖 Top 20% JournalArticle

6 days ago • Korean journal of anesthesiology

Korean expert recommendations on stomach ultrasound before anesthesia and anesthesia care for patients using GLP-1 receptor agonist treatmentsKorean consensus-based recommendations for preanesthetic gastric ultrasound and anesthetic considerations for GLP-1 receptor agonist-based therapy: a consensus statement from Clinical Practice Guideline Committee of the Korean Society of Anesthesiologists.

Article

6 days ago • Journal of integrative neuroscience

Brain-Wide Connections of GLP1R Neurons in the Thalamic Reticular NucleusBrain-Wide Connectivity of GLP1R Neurons in the Thalamic Reticular Nucleus.

📖 Top 30% JournalArticle

6 days ago • Pharmaceutical research

Impurities and Possible Immune Reactions Linked to Generic and Mixed Versions of Glucagon-like Peptide-1 Receptor AgonistsImpurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.

📖 Top 20% JournalArticle

6 days ago • RMD open

Starting tirzepatide and biologic treatments together improves patient-reported outcomes in obese psoriatic arthritisConcurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.

🎖️ Top 10% JournalArticle

6 days ago • Metabolism: clinical and experimental

Genetic evidence shows higher GLP-1 and lower GIP levels may have combined benefits for body weight and heart metabolismComplementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.

🥈 Top 2% JournalArticle

6 days ago • Journal of clinical pharmacology

First Human Study of a Long-Lasting GLP-1 Drug in Overweight or Obese Adults Without Type 2 DiabetesFirst-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus.

Clinical Trial, Phase I

6 days ago • Lancet (London, England)

Effectiveness and safety of once-daily oral zenagamtide, a new combined GLP-1 and amylin receptor drug, in adults with type 2 diabetes: a multi-center, randomized, placebo-controlled dose studyEfficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

🥇 Top 1% JournalArticle

6 days ago • Journal of computer-aided molecular design

Creating a stable peptide drug that activates three hormone receptorsDesign of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.

📖 Top 50% JournalArticle

1 week ago • American journal of physiology. Endocrinology and metabolism

PYY3-36 may enhance Semaglutide's effects on energy control in fatty liver diseasePYY3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLD.

🎖️ Top 10% JournalArticle

1 week ago • Cureus

Blocked Stomach Outlet in an Adult with Ring-Shaped Pancreas After Starting SemaglutideAdult Annular Pancreas Presenting With Gastric Outlet Obstruction Following Semaglutide Initiation: A Case Report.

Case Reports

1 week ago • Cureus

GLP-1 Receptor Agonists and Their Potential Role in Treating Substance Use DisordersA Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.

Article

1 week ago • Case reports in neurology

Nerve Weakness Causing Foot Drop Linked to Leg Crossing After Weight Loss with TirzepatideWeight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss.

Case Reports

1 week ago • Frontiers in oncology

Cancer outcomes and biological effects in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonistsCancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.

📖 Top 20% JournalSystematic Review

1 week ago • Endocrinology and metabolism clinics of North America

Using GLP-1 Receptor Agonists and SGLT Inhibitors Together in Type 1 Diabetes: Reasons, Timing, and Clinical UsesCombination of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents.

🎖️ Top 10% JournalArticle

1 week ago • The American journal of psychiatry

Testing Oral Semaglutide as a Treatment for Alcohol Use DisorderOral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.

🥇 Top 1% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

Guidelines for Using Glucagon-like Peptide-1 Medicines Safely in Adults with Type 1 DiabetesClinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes.

🎖️ Top 10% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: Current Understanding and Future DirectionsDaily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next.

🎖️ Top 10% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

GLP-1 Drugs May Lower Insulin Needs in New Cases of Type 1 DiabetesGLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes.

🎖️ Top 10% JournalArticle

1 week ago • Therapeutic advances in endocrinology and metabolism

Use of GLP-1 Medicines in Primary Care: Preparedness, Fair Access, and the Risk of Unequal Obesity TreatmentGLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.

🎖️ Top 10% JournalArticle

1 week ago • JMIR formative research

Digital Diet Guidance and User Satisfaction During GLP-1 Treatment: A Pilot Study of a Personalized Nutrition ToolClinical Decision Support for Digital Dietary Counseling Under GLP-1 Receptor Agonist Therapy: Convergent Mixed Methods Usability and Treatment Satisfaction Pilot Study of the Personalized Nutrition Advisor.

📖 Top 30% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

Drugs for Kidney Protection in Type 1 Diabetes: Sugar Transport Blockers, Incretin Hormone Boosters, and FinerenoneSodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes.

🎖️ Top 10% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

New Additional Treatments Being Developed for Type 1 DiabetesThe Horizon Ahead: Emerging Adjunctive Therapies for Type 1 Diabetes.

🎖️ Top 10% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

New Evidence That Blood Sugar and Hormone Drugs May Protect Heart and Kidneys in People with Type 1 DiabetesEmerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.

🎖️ Top 10% JournalArticle

1 week ago • Endocrinology and metabolism clinics of North America

Weekly Glucagon-Like Peptide-1 Medicines in Type 1 Diabetes: Current Knowledge and Upcoming StudiesWeekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes: What We Know So Far and Future Trials.

🎖️ Top 10% JournalArticle

1 week ago • AJNR. American journal of neuroradiology

Glucagon-like Peptide-1 Therapy and Thinking Abilities in Patients Treated for Idiopathic High Brain PressureGlucagon-Like Peptide-1 Receptor Agonist Therapy and Neurocognitive Outcomes in Medically Managed Idiopathic Intracranial Hypertension: A Propensity Score-Matched Cohort Study.

Article

1 week ago • Pharmaceuticals (Basel, Switzerland)

New potential medicines for obesity beyond current hormone-based treatmentsA Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy.

📖 Top 20% JournalArticle

← prevpage 3 of 14next →

Latest GLP-1 Therapies Research Papers